EP
PFE icon

Elkhorn Partners’s Pfizer PFE Stock Holding History

Elkhorn Partners’s Portfolio PFE Stock Details PFE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$205K Buy
8,500
+1,100
+15% +$28.8K 0.18% 21
2026
Q1 		$208K Buy
7,400
+400
+6% +$10.6K 0.13% 19
2025
Q4 		$174K Sell
7,000
-3,800
-35% -$95.8K 0.11% 20
2025
Q3 		$275K Hold
10,800
– – 0.19% 18
2025
Q2 		$262K Sell
10,800
-200
-2% -$4.66K 0.19% 19
2025
Q1 		$279K Buy
11,000
+1,500
+16% +$39.3K 0.18% 18
2024
Q4 		$252K Buy
9,500
+3,400
+56% +$92.2K 0.17% 17
2024
Q3 		$177K Sell
6,100
-900
-13% -$26.3K 0.11% 20
2024
Q2 		$196K Buy
7,000
+1,600
+30% +$44K 0.14% 21
2024
Q1 		$150K Buy
5,400
+1,500
+38% +$41.6K 0.11% 23
2023
Q4 		$112K Sell
3,900
-1,400
-26% -$42.3K 0.08% 25
2023
Q3 		$176K Buy
5,300
+700
+15% +$24.8K 0.12% 23
2023
Q2 		$169K Buy
4,600
+400
+10% +$15.6K 0.11% 24
2023
Q1 		$171K Buy
+4,200
New +$181K 0.11% 22

Other funds holding PFE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Elkhorn Partners's PFE Position: Q2 2026 in Review

Elkhorn Partners increased its Pfizer (PFE) stake by 15% in Q2 2026, buying an estimated $28.8K and bringing the position to 8,500 shares worth $205K. The position accounts for 0.18% of the portfolio, ranked #21.

Elkhorn Partners first reported a position in PFE in Q1 2023 and has held it in 14 quarters since. The position peaked at $279K in Q1 2025. 2,827 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

  • Elkhorn Partners held 8,500 shares of Pfizer worth $205K as of Q2 2026.
  • Elkhorn Partners bought 1,100 Pfizer shares in Q2 2026, an estimated $28.8K.
  • Pfizer made up 0.18% of Elkhorn Partners's portfolio in Q2 2026, its #21 holding.
  • Elkhorn Partners first reported a position in Pfizer in Q1 2023 and has held it in 14 quarters since.
  • Elkhorn Partners's Pfizer position peaked at $279K in Q1 2025.
  • 2,827 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on Elkhorn Partners's 13F filing for Q2 2026, filed 13 Aug 2026.